The trajectory of base editing has been remarkable, progressing from the laboratory to patient care, treating debilitating or ...

X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder characterized by high susceptibility to infections that results from genetic mutations in the cytochrome b-245 beta chain ...

Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, ...

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have developed a ...

Researchers have engineered a new class of adenine base editors that reduce unwanted bystander mutations by two to three ...

In this talk in GEN’s “The State of CRISPR & Genome Editing” virtual summit, originally broadcast on June 11, 2025, Alexis Komor, PhD, Associate Professor at University of California San Diego and ...

Add Yahoo as a preferred source to see more of our stories on Google. Futuristic 3D cubes showing DNA base pairs and a double helix. (JuSun via Getty Images) This story was originally published on ...

The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...